|Dr. Joseph K. Belanoff M.D.||Co-Founder, CEO, Pres & Director||1.01M||7.14M||1957|
|Mr. Gary Charles Robb||CFO, Chief Accounting Officer & Sec.||520.68k||N/A||1963|
|Dr. Robert S. Fishman M.D., ? F.C.C.P.||Chief Medical Officer||451.36k||N/A||1962|
|Dr. Hazel Hunt Ph.D.||Sr. VP of Research||N/A||N/A||N/A|
|Donald E. Laferle||Sr. VP||N/A||N/A||N/A|
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Corcept Therapeutics Incorporated’s ISS Governance QualityScore as of March 1, 2018 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 6; Compensation: 8.